|
|
||||||||
Articles |
1
Perkin-Elmer Italy, Monza, Milan, Italy.
a Author for correspondence. Fax +39.55.4377290.
| Abstract |
|---|
|
|
|---|
3' exonuclease activity of Taq
polymerase cleaves the hybridized fluorogenic probe, resulting in an
increase of fluorescence emission of the reporter dye that is
quantitative for the amount of PCR product and, under appropriate
conditions, for the amount of template. Assay performance showed
adequate precision and a lower detection limit and good correlation
with the results obtained in the same samples by a competitive PCR
assay (n = 25, r = 0.94, P <0.01).
This homogeneous assay is time-saving, avoids usually cumbersome
postamplification procedures (that can be additional sources of
inaccuracy and contamination), and seems suitable for determination of
c-erbB-2 oncogene amplification in tumor
specimens.
Key Words: indexing terms: breast cancer genetic alterations oligonucleotide probes fluorescence assays
| Introduction |
|---|
|
|
|---|
Recently, detection of specific PCR products with fluorogenic probes has been proposed (11)(12)(13)(14). The probes are designed to hybridize within the target sequence and to generate a signal that accumulates during PCR cycling in proportion to the accumulation of amplification products. The end-point measurement of fluorescence in each sample thus provides a homogeneous signal that is specifically associated with the amplified target and quantitatively related to the amount of PCR products, without requiring further post-PCR procedures.
To verify the applicability of this approach to quantitative PCR, we developed an assay for measuring c-erbB-2 amplification in DNA from human breast tumors. Protooncogene amplification has been consistently observed in human tumors and, although no direct correlation between gene amplification and the pathogenic mechanisms of tumorigenesis has been clearly established, in several cases detection of oncogene amplification can serve as a genetic marker for prognosis. In particular, several authors have reported a direct correlation between c-erbB-2 amplification in breast carcinoma and clinical outcome (15)(16)(17)(18).
In this study, we used the instrumentation and the fluorogenic probes of the Perkin-Elmer Cetus (Norwalk, CT) LS-50B TaqManTM System (19). The results were compared with those of a previously assessed competitive PCR method for measuring c-erbB-2 oncogene amplification (8)(9).
| Materials and Methods |
|---|
|
|
|---|
3' exonuclease activity of
Taq DNA polymerase (19) (Fig. 1A
|
The sequence of the probes utilized in this report to detect ß-actin,
ß-globin, and c-erbB-2 genes is reported in Table 1
. Probes were designed according to the manufacturer's
guidelines (19). Briefly, the TaqMan probe should
(a) be 2040 bases long, to ensure good hybridization and
specificity of binding; (b) have a GC content of 4060%
and avoid long runs of a single nucleotide; and (c) neither
hybridize nor overlap with the forward and reverse primers. It is
important to design a probe that forms a more stable hybrid than do the
PCR primers; thus, the melting temperature (Tm)
of the probe should be at least 5 °C higher than that of the PCR
primers. Synthesis and purification of the fluorogenic probes was
performed by Perkin-Elmer Cetus. The detection system for ß-actin
gene, provided by the manufacturer as "reference detection
reagents" (code 401846), was used for preliminary assessment of the
PCR conditions.
|
tumor samples and dna extraction
We used the proposed method to measure amplification of
c-erbB-2 oncogene in 25 primary breast tumors
(amplification range 122-fold), in which the presence of this genetic
alteration had already been determined with a previously described
competitive PCR procedure (8)(9), and in DNA
specimens obtained from formalin-fixed, paraffin-embedded breast tumor.
DNA was extracted from archived samples after deparafinization, as
reported elsewhere (22), by a routine phenolchloroform
procedure (23).
Histopathological classification of the tumor samples was as follows: The tumor stage was pT1a in 2 cases, pT1b in 3, pT1c in 9, pT2 in 9, and pT4 in 2 cases; the nuclear grade was G3 in 14 cases, G2 in 9, and G1 in 2. Eighteen patients showed nodal involvement at the time of surgery.
pcr conditions
For PCR amplification, we utilized a Model 480 thermal cycler from
Perkin-Elmer Cetus. The 10x PCR Buffer; the mononucleotides dATP,
dCTP, dGTP, and dTTP; and the AmpliTaq DNA Polymerase were also from
Perkin-Elmer. The PCR mix used for the TaqMan system was: 10 mmol/L
Tris-HCl (pH 8.3), 50 mmol/L KCl, 1.5 mmol/L MgCl2 (3.5
mmol/L MgCl2 for the ß-actin gene), 0.2 mmol/L of each
dNTP, 0.3 µmol/L of each primer, 0.2 µmol/L of each probe, and 1.25
U of AmpliTaq (Perkin-Elmer Cetus) in a 50-µL final volume. The PCR
cycles for ß-globin and for c-erbB-2 were: 30 s at
94 °C, 30 s at 60 °C, and 30 s at 72 °C. For
ß-actin amplification, the PCR conditions were: 30 s at
94 °C, 30 s at 54 °C, and 30 s at 72 °C. Primer
sequences are reported in Table 1
.
fluorescence measurement and calculations
The fluorescence was measured with a luminescence spectrometer
(Model LS-50B; Perkin-Elmer) equipped with a plate reader (see Fig. 2
). We adopted a standard configuration for use in the three
assays: 488 nm excitation wavelength; 518 and 580 nm emission
wavelengths for the reporter and quencher dyes, respectively; and a 2-s
integration time. After PCR cycling, a maximum of 40 µL from each
sample or blank was transferred to a microwell.
|
As previously described [19], the fluorescent
signal results from changes in the fluorescence emission intensity of
the reporter dye after the cleavage of the probe. Interfering
fluorescence fluctuations are normalized by applying two calculations.
In the first, the quencher dye is a passive internal standard; we
divide the emission intensity of the reporter dye by the emission
intensity of the quencher dye for each reaction to give a ratio defined
as the RQ+ value. Nonspecific effects, e.g.,
concentration changes resulting from volume fluctuations, are
normalized by this ratio. Any other fluctuation, besides that
attributable to PCR-related nuclease digestion, is normalized by taking
the RQ+ value for a sample tube that contains all
components (including target DNA) and subtracting from this the value
of the "no-template" control tube, i.e., containing all of the same
components except template and defined as RQ-. This final
RQ value (i.e., RQ+ - RQ-) reliably
indicates the magnitude of the signal generated by the given set of PCR
conditions (19). Calculations and procedures for
fluorescence signal acquisition are obtained with a personal computer
connected on-line with the LS-50B luminescence spectrometer and
equipped with a proprietary software specifically developed for the
TaqMan technology.
| Results |
|---|
|
|
|---|
RQ measured
at 28, 31, and 34 cycles, as related to the amount of target DNA,
showed a better dose-dependent response in the range between 28 and 31
cycles (Fig. 3B
|
taqman pcr assay conditions for ß-globin and
c-erbb-2 genes
Using the fluorogenic probes for ß-globin and
c-erbB-2 and the experimental conditions previously
defined for the ß-actin gene, we obtained a linear relationship
between the DNA concentration and the fluorescent signal (
RQ) for
ß-globin and c-erbB-2 genes in 2.520 ng of DNA target.
Even if the linear response for the two genes showed different slope
coefficients (mainly attributable to differences in efficiencies of
fluorescence-generating reactions), the c-erbB-2/ß-globin
fluorescence ratio was constant in this range of target concentrations
of normal DNAs (Fig. 4
).
|
measuring c-erbb-2 amplification in breast tumor
specimens
To determine the amplification extent of c-erbB-2
oncogene in breast tumor specimens, we tested 2.5 ng each of ß-globin
and c-erbB-2 in different tubes but in the same run. Four
replicates of human placental DNA were also assayed for both ß-globin
and c-erbB-2 genes. For each unknown sample, we determined
the
RQ values for both genes as well as the
c-erbB-2/ß-globin ratio. Finally, we divided this ratio by
the mean c-erbB-2/ß-globin fluorescence ratio obtained in
placental DNA samples. When c-erbB-2 amplification values
were >10, the DNA sample being measured was diluted before the TaqMan
PCR assay.
assay performance
To test the precision of TaqMan-based PCR assay, we measured in
the same assay the
RQ values for c-erbB-2 in 10
replicates of normal DNA, starting with two different template amounts
(2.5 and 8 ng). The intraassay CV of the
RQ values for
c-erbB-2 in each template was 3.3% and 4.7%, respectively.
The interassay precision in 6 different runs was 15.4% and 17.3%,
respectively.
We tested the capacity of the TaqMan system to discriminate between
different-fold c-erbB-2 amplifications by measuring the
amplification in reconstituted samples obtained by serial dilutions in
placental DNA of a DNA extracted from the SKBR.3 cell line carrying an
11-fold c-erbB-2 amplification (24). The
results are reported in Fig. 5
.
|
To verify the correspondence with classical hybridization techniques,
we quantified c-erbB-2 amplification by the proposed
method in four breast cancer cell lines (SKBR-3, ZR75.1, T47D, and
MDA.MB.231) in which the oncogene amplification had been previously
measured with Southern transfer analysis (Table 2
).
|
Finally, we determined the amplification of c-erbB-2 in
DNA extracted from 25 formalin-fixed, paraffin-embedded breast tumor
samples in which the oncogene amplification had already been documented
by a competitive PCR assay. The results obtained with the two PCR-based
techniques showed a good correlation: r = 0.94,
P <0.001 (Fig. 6
).
|
| Discussion |
|---|
|
|
|---|
Accurate quantitative procedures for measuring nucleic acids, combined with the high sensitivity of PCR, are new and suitable tools for addressing specific requirements of diagnostic investigations (as in determinations of oncogene amplification) and are now becoming available for use in the clinical laboratory (32). However, up-to-date, independent, quantitative PCR methods usually require cumbersome postamplification procedures that can be additional sources of inaccuracy and contamination.
The novel procedure reported here allows accurate determination of PCR-amplified targets by a homogeneous technique. The specific signal derived by the use of a fluorogenic probe accumulates during PCR cycling and can easily be measured by end-point evaluation of specific fluorescence. The only difference between this system and other routine PCR procedures is the addition of a single reagent to the reaction mixture: a fluorogenic probe designed to anneal to the target sequence. In this sense, this system provides simultaneously (a) the desired information for quantitative evaluation and (b) qualitative recognition of the amplified target. The presence of a specific internal probe, carrying the signal-generating system, guarantees the specificity of the PCR product to be measured. Further, the intensity of the fluorescence signal allows the detection of PCR products in samples originally containing low quantities of DNA templates, even after a limited number of PCR cycles.
Oncogene amplification is a common quantitative alteration in tumoral DNA; therefore, we chose the increase of c-erbB-2 oncogene copy number as a suitable model for developing a quantitative TaqMan PCR assay. We first assessed the PCR conditions that would yield a linear response between DNA target doses and fluorescence signal from amplified productsthe preliminary requirement for assessing a quantitative assay in the exponential phase of PCR. Using ß-actin, ß-globin, and c-erbB-2 fluorescent probes, we determined the range of both the number of PCR cycles and the amounts of DNA that should be used for maintaining the linear relationship between amplified target and PCR-generated product. These preliminary data were then applied to the development of the assay for c-erbB-2 amplification. Results for DNA extracted from paraffin blocks of 25 breast primary tumors, which provided only limited quantities of variable degraded DNA unsuitable for Southern transfer analysis, were compared with those obtained with an already developed competitive PCR procedure. This latter method is known to provide highly accurate and sensitive results, but the procedure (competitor construction, assessment of competitive PCR conditions, and measurement of PCR products) is quite complex. However, the TaqMan PCR assay described here represents a promising approach to obtaining reasonable accuracy for a quantitative PCR assay. The TaqMan PCR assay gave results comparable with those of Southern transfer analysis in DNA extracted from four breast cancer cell lines.
We conclude that the TaqMan procedure is easily applicable to qualitative applications in its standard configuration but, when the PCR conditions are well standardized and the exponential phase is well controlled, can also be successfully extended to quantitative applications. Our results showed a good agreement between the TaqMan assay and competitive PCR for determining the extent of c-erbB-2 amplification. Further, evaluation of precision and accuracy seems to indicate reliability of the TaqMan procedure for this measurement, apparently opening further improvements for quantitative PCR methods. However, further methodological studies will be necessary to confirm that the TaqMan methodology can be considered an accurate and sensitive quantitative PCR methodology.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
The following articles in journals at HighWire Press have cited this article:
![]() |
T. Gotoh, H. Hosoi, T. Iehara, Y. Kuwahara, S. Osone, K. Tsuchiya, M. Ohira, A. Nakagawara, H. Kuroda, and T. Sugimoto Prediction of MYCN Amplification in Neuroblastoma Using Serum DNA and Real-Time Quantitative Polymerase Chain Reaction J. Clin. Oncol., August 1, 2005; 23(22): 5205 - 5210. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Soldati, D. Adamo, C. Bianchin, T. Arcidiacono, A. Terranegra, M. L. Bianchi, S. Mora, D. Cusi, and G. Vezzoli Vitamin D Receptor mRNA Measured in Leukocytes with the TaqMan Fluorogenic Detection System: Effect of Calcitriol Administration Clin. Chem., August 1, 2004; 50(8): 1315 - 1321. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Woelfle, J. Cloos, G. Sauter, L. Riethdorf, F. Janicke, P. van Diest, R. Brakenhoff, and K. Pantel Molecular Signature Associated with Bone Marrow Micrometastasis in Human Breast Cancer Cancer Res., September 15, 2003; 63(18): 5679 - 5684. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Garcia-Quintanilla, J. Gonzalez-Martin, G. Tudo, M. Espasa, and M. T. Jimenez de Anta Simultaneous Identification of Mycobacterium Genus and Mycobacterium tuberculosis Complex in Clinical Samples by 5'-Exonuclease Fluorogenic PCR J. Clin. Microbiol., December 1, 2002; 40(12): 4646 - 4651. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Mackay, K. E. Arden, and A. Nitsche Real-time PCR in virology Nucleic Acids Res., March 15, 2002; 30(6): 1292 - 1305. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. C. Kischkel, D. A. Lawrence, A. Tinel, H. LeBlanc, A. Virmani, P. Schow, A. Gazdar, J. Blenis, D. Arnott, and A. Ashkenazi Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8 J. Biol. Chem., November 30, 2001; 276(49): 46639 - 46646. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Becker, P. Böger, R. Oehlmann, and A. Ernst PCR Bias in Ecological Analysis: a Case Study for Quantitative Taq Nuclease Assays in Analyses of Microbial Communities Appl. Envir. Microbiol., November 1, 2000; 66(11): 4945 - 4953. [Abstract] [Full Text] |
||||
![]() |
P. Willems, O. Verhagen, C. Segeren, P. Veenhuizen, J. Guikema, E. Wiemer, L. Groothuis, T. B.-d. Jong, H. Kok, A. Bloem, et al. Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study Blood, July 1, 2000; 96(1): 63 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Sgroi, S. Teng, G. Robinson, R. LeVangie, J. R. Hudson Jr., and A. G. Elkahloun In Vivo Gene Expression Profile Analysis of Human Breast Cancer Progression Cancer Res., November 1, 1999; 59(22): 5656 - 5661. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Raggi, M. L. Bagnoni, G. P. Tonini, M. Maggi, G. Vona, P. Pinzani, K. Mazzocco, B. De Bernardi, M. Pazzagli, and C. Orlando Real-Time Quantitative PCR for the Measurement of MYCN Amplification in Human Neuroblastoma with the TaqMan Detection System Clin. Chem., November 1, 1999; 45(11): 1918 - 1924. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-W. Chiang, D. G. Beer, W.-L. Wei, M. B. Orringer, and D. M. Kurnit Detection of erbB-2 Amplifications in Tumors and Sera from Esophageal Carcinoma Patients Clin. Cancer Res., June 1, 1999; 5(6): 1381 - 1386. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.-M. Norton and C. A. Batt Detection of Viable Listeria monocytogenes with a 5' Nuclease PCR Assay Appl. Envir. Microbiol., May 1, 1999; 65(5): 2122 - 2127. [Abstract] [Full Text] |
||||
![]() |
G.J. Nuovo, R.J. Hohman, G.A. Nardone, and I.A. Nazarenko In Situ Amplification Using Universal Energy Transfer-labeled Primers J. Histochem. Cytochem., March 1, 1999; 47(3): 273 - 280. [Abstract] [Full Text] |
||||
![]() |
C. Gonzalez-Manchon, M. Fernandez-Pinel, E. G. Arias-Salgado, M. Ferrer, M.-V. Alvarez, S. Garcia-Munoz, M. S. Ayuso, and R. Parrilla Molecular Genetic Analysis of a Compound Heterozygote for the Glycoprotein (GP) IIb Gene Associated With Glanzmann's Thrombasthenia: Disruption of the 674-687 Disulfide Bridge in GPIIb Prevents Surface Exposure of GPIIb-IIIa Complexes Blood, February 1, 1999; 93(3): 866 - 875. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ferrer, J. Tao, G. Iruin, M. Sanchez-Ayuso, J. Gonzalez-Rodriguez, R. Parrilla, and C. Gonzalez-Manchon Truncation of Glycoprotein (GP) IIIa (triangle 616-762) Prevents Complex Formation With GPIIb: Novel Mutation in Exon 11 of GPIIIa Associated With Thrombasthenia Blood, December 15, 1998; 92(12): 4712 - 4720. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sundaresan, P. E. Roberts, K. L. King, M. X. Sliwkowski, and J. P. Mather Biological Response to ErbB Ligands in Nontransformed Cell Lines Correlates with a Specific Pattern of Receptor Expression Endocrinology, December 1, 1998; 139(12): 4756 - 4764. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yajima, A. Yagihashi, H. Kameshima, D. Kobayashi, D. Furuya, K. Hirata, and N. Watanabe Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system Clin. Chem., December 1, 1998; 44(12): 2441 - 2445. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hirayama, S. Sakamaki, T. Matsunaga, T. Kuga, H. Kuroda, T. Kusakabe, K. Sasaki, K. Fujikawa, J. Kato, K. Kogawa, et al. Concentrations of Thrombopoietin in Bone Marrow in Normal Subjects and in Patients With Idiopathic Thrombocytopenic Purpura, Aplastic Anemia, and Essential Thrombocythemia Correlate With Its mRNA Expression of Bone Marrow Stromal Cells Blood, July 1, 1998; 92(1): 46 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Bor, B. S. Sorensen, P. Rammer, and E. Nexo Calibrated user-friendly reverse transcriptase-PCR assay: quantitation of epidermal growth factor receptor mRNA Clin. Chem., June 1, 1998; 44(6): 1154 - 1160. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Whitcombe, J. Brownie, H. L. Gillard, D. McKechnie, J. Theaker, C. R. Newton, and S. Little A homogeneous fluorescence assay for PCR amplicons: its application to real-time, single-tube genotyping Clin. Chem., May 1, 1998; 44(5): 918 - 923. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |